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Cancer patients frequently exhibit a deficiency in Type-1 (but not Type-2 or regulatory)
CD4+ T cell responses against tumor-associated antigens (TAA), which may limit protec-
tion against disease progression or responsiveness to immunotherapy in these individuals.
Since such deficiency was acutely evident in patients with active disease (AD), where
chronic stimulation of anti-tumor CD4+ T cells would be expected and activation-induced
cell death may be prevalent, we employed MHC Class II-peptide tetramers to character-
ize the frequency and apoptotic status of TAA- vs. influenza (FluM1) virus-specific CD4+ T
cells in the peripheral blood of HLA-DR*0401+ patients with melanoma or renal cell car-
cinoma. We observed that Flu-specific CD4+ T cells ranged from 0.17 to 3.89%, while
up to approximately 1% of CD4+ T cells reacted against individual TAA epitopes derived
from the EphA2 or MAGE-6 proteins. The frequencies of EphA2 and MAGE-6-specific
CD4+ T cells in patients were significantly correlated with AD and gender of the patient
(i.e., females>males), while frequencies of Flu-specific CD4+ T cells were distributed
within a normal range in all patients. Notably, patient CD4+ T cells reactive with MHC
class II-TAA (but not MHC class II-Flu) tetramers were significantly enriched for a pro-
apoptotic (Annexin-V+) phenotype, particularly amongst the Th1 (T-bet+) subset. These
results suggest that the preferential sensitivity of TAA (but not viral)-specific CD4+ Th1
cells to apoptosis in melanoma patients with AD will need to be overcome for optimal
clinical benefit of immunotherapeutic approaches to be realized.
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INTRODUCTION
Effective immunotherapy in the cancer setting is believed to be
largely dependent upon the activation of endogenous CD8+ T
effector cells that are capable of mediating sustained anti-tumor
effector functions in vivo (1–7). Despite the ability of vaccines
and immunotherapies to reproducibly augment circulating lev-
els of CD8+ T cells reactive against tumor-associated antigens
(TAA) in the peripheral blood of patients, rates for objective clin-
ical responses in these trials have been disappointingly modest
(8). These results support second-set deficiencies in the ability
to effectively target and sustain circulating effector CD8+ T cells
into/within sites of disease in vivo (9–11).
Type-1 CD4+ T (Th1) cells in particular appear crucial for
optimal induction, recruitment, and long-term maintenance of
therapeutic anti-tumor CD8+ T cells and anti-tumor immunity
(12–15). Furthermore, CD4+ Th1-type helper cells are required
for the reactivation and expansion of effector CD8+ T cells
from memory precursors (16). Unfortunately, we and others have
demonstrated that TAA (such as EphA2 and MAGE6)-specific,
Th1 cell function is deficient in many cancer patients and that
increased frequencies of TAA-reactive Th2- or Treg-type CD4+ T
cells may be functionally dominant in vivo (17, 18), leading to a
suppression of anti-tumor CD8+ T cell function (19, 20). The rea-
son for biased Th1 dysfunction in cancer patients remains poorly
understood.
Given reports that Type-1 CD4+ T cells are subjected to
chronic antigen-stimulation making them differentially (vs. Type-
2 or Treg) sensitive to activation-induced cell death (AICD)
via an apoptotic mechanism (21), we hypothesized that TAA-
specific CD4+ T cells freshly isolated from the peripheral blood
of melanoma or renal cell carcinoma (RCC) patients with active
disease (AD) would have a higher likelihood of exhibiting a pro-
apoptotic phenotype. Based on our previous work supporting the
common presence of anti-EphA2 and anti-MAGE6 CD4+ T cells
in the peripheral blood of HLA-DR4+ patients with melanoma or
RCC based on cytokine-based ELISPOT readout assays (17, 22),
we now analyzed similar patients for the status of antigen-specific
CD4+ T cells at the single cell level by flow cytometry by imple-
menting fluorescently labeled MHC Class II-peptide tetramers.
Our results suggest that patients with AD have greater frequencies
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of TAA-specific CD4+ T cells than patients rendered clinically
free of disease, but that many of these antigen-specific T cells are
actively undergoing apoptotic programing. These findings indi-
cate that preferential death among TAA-specific CD4+ T cells likely
contributes to anti-tumor immune dysfunction in patients and
suggest that the therapeutic administration of stimuli to improve
the survival and poly-functionality of anti-TAA Th1 cells may yield
improved therapeutic benefit(s) to patients afflicted with cancers
such as melanoma.
MATERIALS AND METHODS
ISOLATION OF PBMC AND HLA TYPING
Peripheral blood was obtained by venipuncture from melanoma
or RCC patients with their written consent under IRB-approved
protocols. Peripheral blood mononuclear cells (PBMC) were
isolated by density gradient separation (d < 1.077; endotoxin-
free Histopaque, Sigma; St. Louis, MO, USA) and washed twice
in phosphate buffered saline (PBS, pH 7.4; Life Technologies,
Grand Island, NY, USA), then re-suspended in AIM-V medium
(Invitrogen-Life Technologies, Carlsbad, CA, USA), and stored at
room temperature (RT) overnight. HLA-DR4 positive donors were
identified by flow cytometry using the 359-F10 mAb as previously
described (23).
CD4+ T CELL ISOLATION
CD4+ T cells were obtained from fresh PBMC using positive selec-
tion with MACS paramagnetic beads (Miltenyi; Auburn, CA, USA)
on MiniMACS columns, according to manufacturer’s protocol and
used for tetramer staining. In some cases, CD4+ T cells were iso-
lated by negative selection (StemCell Technologies; Vancouver, BC,
Canada), where indicated. Purity (>95%) was verified by flow
cytometry after labeling isolated cells with CD3-FITC and CD4
PE (BD-PharMingen; San Diego, CA, USA).
DETECTION OF ANTIGEN-SPECIFIC CD4+ T CELLS BY FLOW
CYTOMETRY
Peptide epitopes used in the construction of HLA-DR4-
tetramers included: MAGE-6121–144, MAGE-6246–263, EphA253–68,
EphA263–75, EphA2663–677, and inFluenza A matrix 60–73 (FluM1)
(17, 18, 24). Peptides were synthesized using FMOC chemistry
by the University of Pittsburgh Cancer Institute’s (UPCI) pep-
tide synthesis facility (shared resource). Peptides were>90% pure
based on HPLC profile and MS/MS mass spectrometric analy-
sis performed by the UPCI protein sequencing facility (shared
resource). PE-labeled HLA-DR4-tetramers were constructed using
these HLA-DR4 restricted epitopes as previously described (25).
For detection of antigen-specific cells, CD4+ T cells (5× 105) were
washed in FACScan buffer [0.2% BSA, 0.02% NaN3 (Sigma) in
PBS] then incubated with human IgG (Sigma; 1 mg/ml in FAC-
Scan buffer) as a blocking reagent for 10 min. Cells were then
incubated with PE-labeled HLA-DR4/peptide tetramers for 1 h
at RT in the dark, then transferred for an additional 30 min
incubation on ice in the presence of various mAb to surface
markers [anti-CCR5-FITC, CD45RO-FITC, CD62L-CyChrome,
CD25 FITC (BD-PharMingen), anti-CCR3-FITC (R & D Sys-
tems; Minneapolis, MN, USA)]. As a negative control, cells
were stained in parallel with irrelevant isotype control mAbs
(unconjugated or conjugated with FITC or CyChrome). Where
noted, PBMC rather than isolated CD4+ T cells were used and
anti-CD4-FITC (BD-Pharmingen) was used to identify CD4+ T
lymphocytes co-binding PE-labeled HLA-DR4/peptide tetramers.
After incubation(s) with mAb to surface antigens, cells were
washed once in FACScan buffer and once in binding buffer
[0.01 M Hepes (pH 7.4), 0.14 M NaCl, 2.5 mM CaCl2]. Apop-
totic cells were detected by incubation with Annexin-V-biotin
(BD-Pharmingen) for 15 min at RT, washed in binding buffer
then incubated with Streptavidin (SA)-PerCP (BD-PharMingen)
for 15 min at RT. Labeling of cells with PE-conjugated HLA-
DR4/peptide tetramers followed by SA-PerCP (in the absence
of annexin-V-biotin) did not result in SA-PerCP binding by
tetramer+ cells as determined by flow cytometry, indicating that
SA-PerCP (used to detect of annexin-V-biotin labeled apop-
totic cells) did not bind to the biotin component of HLA-DR4-
tetramers. Finally, cells were re-suspended in binding buffer (or
FACScan buffer in instances where apoptosis was not being mea-
sured) prior to analysis on an EPICS-XL flow cytometer, with
greater than 100,000 events were evaluated (Beckman-Coulter;
Fullerton, CA, USA). For four-color flow cytometry, staining com-
binations included (1) anti-Tbet-FITC (Biolegend; San Diego,
CA, USA), HLA-DR4/peptide tetramer-PE, annexin-V-biotin/SA-
PerCP, with or without 7-AAD, (2) various FITC-mAb to surface
markers combined with HLA-DR4 tetramer-PE and anti-CD62L-
CyChrome. Combination cell surface marker and intracellular
staining for T-bet was performed as previously described (26).
Flow cytometry data were then analyzed using WinMDI software
version 2.8.
STATISTICAL ANALYSIS
SigmaStat software was used to analyze data. Statistically signif-
icant differences (p< 0.05) were determined using paired and
un-paired T -tests.
RESULTS
QUANTITATION OF TAA-SPECIFIC CD4+ T CELL FREQUENCIES IN THE
PERIPHERAL BLOOD OF PATIENTS WITH MELANOMA: CORRELATION
WITH DISEASE STATUS
To determine the frequency of circulating anti-TAA Th cells in
HLA-DR*0401+ melanoma patients, CD4+ T cells were freshly
isolated from patient peripheral blood (Table 1) and incu-
bated with PE-labeled HLA-DR4 tetramer complexes contain-
ing the MAGE-6121–144, MAGE-6246–263, EphA253–62, EphA263–75,
EphA2663–678 TAA epitopes, or the (positive control) influenza A
matrix (FluM1)60–73 viral epitope, then analyzed by flow cytom-
etry (Figure 1). Frequencies of CD4+ T cells binding HLA-
DR4/FluM1-tetramers in patients ranged from 0.17 to 3.89%
(average 1.07± 1.07%, n= 15; Figure 1), with these levels signifi-
cantly exceeding (p< 0.005) those noted for CD4+ T cells binding
any given HLA-DR4/TAA peptide tetramer that ranged from 0.01
to 0.95% (average 0.18± 0.16%,n= 15). Isolation of CD4+ T cells
by either positive or negative selection prior to tetramer analysis
did not alter binding to HLA-DR4-tetramers, as the frequencies of
tetramer+ cells detected within the isolated CD4+ T cell popula-
tions were equivalent to those detected in whole PBMC gated on
CD4+ lymphocytes (data not shown).
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Table 1 | Clinical characteristics of melanoma patients evaluated in this study.
Melanoma
patient no.
Age Gender (M/F) Disease stage Disease status Disease status at
study conclusion
Previous
treatment(s)
Mel031 53 M II NED NED S
Mel032 54 M III AD NED S, I
Mel036 48 F II NED UN S
Mel039 65 M IV AD Deceased S
Mel043 39 M IV AD Deceased S
Mel046 52 F III AD AD S
Mel048 32 F III AD AD S
Mel049 34 M III AD Deceased S, I, C
Mel060 45 M IV AD Deceased S
Mel073 52 M IV AD NED S, I
Mel093 46 M IV AD Deceased S, I, C
Mel094 57 F II AD NED S
Mel096 28 F III NED NED S
Mel103 66 F IV AD NED S, R, C
Mel104 67 F IV AD Deceased R
Mel612 38 M IV AD Deceased S, C
Mel633 56 M II NED AD S, I
Mel634 51 M IV AD Deceased S, I, C
Mel635 81 M IV AD Deceased S
AD, active disease; C, chemotherapy; I, immunotherapy; NED, no evidence of disease; PBMC, peripheral blood mononuclear cells; R, radiotherapy; S, surgery; UN,
unknown.
To determine whether the presence of melanoma affected the
frequencies of TAA-specific CD4+ T cells in patients, we analyzed
MAGE-6- or EphA2-reactive CD4+ T cells in individuals with no
evidence of disease (NED) vs. patients with AD. While we observed
no significant difference in the frequency of Flu-specific CD4+ T
cells between these two patient populations (p= 0.39), we deter-
mined that frequencies of pooled TAA-specific CD4+ T cells in
patients with AD were significantly increased when compared with
patients who had been rendered NED as a consequence of prior
therapy (p< 0.008; Figure 2A). Interestingly, TAA-specific CD4+
T cell frequencies in female patients were elevated (approximately
twofold) when compared to male patients (p< 0.05), while Flu-
specific CD4+ T cell frequencies were not significantly different
between these patient cohorts (p= 0.29) (Figure 2B). Further-
more, we identified a trend for increased frequencies of TAA- (but
not FluM1-) specific CD4+ T cells as a function of disease stage,
although this did not reach statistical significance (Figure 3 and
data not shown).
MELANOMA TAA-SPECIFIC CD4+ T CELLS IN PATIENTS ARE NOT
BIASEDWITH REGARD TO NAÏVE/MEMORY/EFFECTOR OR REGULATORY
PHENOTYPES
To determine whether freshly isolated TAA-specific T cells
in patients were of the naïve, memory, or effector pheno-
type, we assessed expression of the CD45RO and CD62L
markers on tetramer+ CD4+ T cells. We observed that
TAA epitope-specific CD4+ T cells were typically het-
erogeneous in nature, containing sub-populations corre-
sponding to naïve (CD45RO−CD62L+), central memory
(CD45RO+CD62L+), memory-effector (CD45RO+CD62L−),
and effector (CD45RO−CD62L−) cells, with the patterns and sub-
set distributions for TAA-specific CD4+ T cells similar to those
obtained for patient-matched Flu-specific CD4+ T cells (Figure S1
in Supplementary Material). To determine whether TAA-specific
T cells bearing a Treg phenotype were present in the peripheral cir-
culation of melanoma patients; we analyzed tetramer+ CD4+ T
cells for co-expression of CD25hi+. Among the patients evaluated,
we determined that 5–15% of total CD4+ T cells were CD25hi+,
regardless of“specificity”(i.e.,HLA-DR4/FluM1-tetramer+CD4+
T cells vs. HLA-DR4/TAA peptide tetramer+; data not shown).
Thus, for a given patient, there was no apparent disease-associated
bias in the naïve/effector/memory or regulatory-like phenotypes
of TAA-specific CD4+ T cells.
CIRCULATING TAA (BUT NOT FLU)-SPECIFIC CD4+ T CELLS ARE
COMMONLY PRO-APOPTOTIC IN MELANOMA PATIENTS AND
ENRICHED WITHIN THE TYPE-1 (T-bet+) SUB-POPULATION
Given our previous findings of functional deficiency in the Type-
1 TAA-specific CD4+ T cell responses in melanoma and RCC
patients (17, 18) and reports for the preferential sensitivity of
Th1-type CD4+ T cells to AICD under conditions of chronic
antigen-stimulation (27, 28), we next investigated whether HLA-
DR4/TAA peptide tetramer+ CD4+ T cells in patients were
prone to express an Annexin-V+ pro-apoptotic phenotype, and
whether such phenotypes diverged from those associated with
HLA-DR4/FluM1-tetramer+ CD4+ T cells (Figure 4A). While
Annexin-V+ events were not common among total CD4+ T cells
or HLA-DR4/FluM1-tetramer+ CD4+ T cells (i.e., 8.1± 6.6%)
in a given patient, CD4+ T cells binding HLA-DR4/TAA peptide
tetramers in patients displayed significantly elevated frequencies
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FIGURE 1 | Flow cytometric analysis of antigen-specific CD4+ T cells
isolated from melanoma patients. (A) Representative plots of flow
cytometry analysis of HLA-DR*0401/peptide tetramer+CD4+ T cells from two
melanoma patients (Mel046, Mel048). Live cells were gated based on
forward and side scatter. Regions used to enumerate frequencies of (FluM1
or individual EphA2 or MAGE6 TAA) tetramer-reactive CD4+ T cells are shown.
(B) Composite data obtained from flow cytometry analysis of CD4+ T cells
using the indicated PE-labeled HLA-DR4/peptide tetramer probes in 15
HLA-DR*0401+ melanoma patients (Table 1; Mel031-Mel104). Box plots
represent the range of responses for all patients, with mean frequencies
shown as solid horizontal lines, and with whisker bars representing 5th and
95th percentiles for each HLA-DR4/peptide tetramer analyzed.
of Annexin-V+ sub-populations (p< 0.01 for each TAA epitope;
n= 13; Figure 4B). Interestingly, the frequency of pro-apoptotic
events among (FluM1- or TAA-) tetramer+ CD4+ T cells was not
correlated with gender, age, or NED/AD status (data not shown) of
patients. Although not reaching statistical significance, there was
a trend for even FluM1- (in addition to TAA-) specific CD4+ T
cells to exhibit elevated (i.e.,>10%) frequencies of pro-apoptotic
sub-populations in late-stage disease (Figure 5).
To determine the frequency of antigen-specific CD4+ T cells
that were Type-1 polarized and undergoing apoptosis, we per-
formed multi-parameter flow cytometry including intracellular
staining for T-bet, a transcription factor required for Th1 differen-
tiation [(29); Figure 6]. We observed that TAA-specific Th1 cells
were readily detectable in the circulation of melanoma patients,
but that these cells represented a minority of total tetramer+ events
in all cases (Figure 6A) and that these cells were preferentially
undergoing apoptosis when compared with the T-bet− subset of
TAA-specific CD4+ T cells (Figure 6B). Indeed, for all TAA speci-
ficities evaluated, approximately 40–80% of the Th1 (T-bet+) sub-
population exhibited a (pro)apoptotic phenotype (Annexin-V+;
Figure 6C).
DISCUSSION
Based on our previous studies documenting Type-1 tumor-specific
CD4+ T cell dysfunction in the peripheral blood of patients with
melanoma or RCC (17, 18, 22), the current studies were developed
to provide further insights into potential mechanisms that may
underlie such deficiency in the advanced disease setting. Our past
work utilized cytokine ELISPOT assays to enumerate and inter-
rogate patient CD4+ T cell reactivity against specific HLA-DR4-
presented epitopes derived from TAA such as EphA2 and MAGE-6.
However, ELISPOT assays did not allow for multi-parameter
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FIGURE 2 | Frequency of MAGE-6-, EphA2-, and Flu-specific CD4+ T
cells in melanoma patients varies based on disease status and gender.
(A) Frequencies of antigen-specific CD4+ T cells in patients with active
disease (AD; n=8) vs. no evidence of disease (NED; n=7) were
determined using PE-labeled HLA-DR4/peptide tetramers and flow
cytometry as described in Figure 1 and Section “Materials and Methods.”
Composite data are depicted in Box plots. The means are represented as
solid horizontal lines, whisker bars representing 5th and 95th percentiles,
and outliers are represented by dots. Left graph represents FluM1-specific
CD4+ T cells and the right graph represents pooled (three EphA2
epitopes+ two MAGE6 epitopes) TAA-specific responses. (B) Frequencies
of antigen-specific CD4+ T cells from seven male and eight female patients
(no difference in age, disease stage, or presence/absence of disease) were
determined using PE-labeled HLA-DR4/peptide tetramers and flow
cytometry as indicated in Figure 1 and Section “Materials and Methods.”
Symbols indicate data for individual patients, with mean frequencies
indicated by heavy horizontal bars.T -test analysis was used to compare
male vs. female patients, with p-values of differences between
male/female cohorts indicated.
assessment of epitope-specific CD4+ T cells to be pursued. Based
on their ability to mark specific CD4+ T cells in multi-color
flow cytometry assays, we developed HLA-DR4/peptide tetramers
incorporating each of five previously defined TAA-derived epi-
topes: MAGE-6121–144, MAGE-6246–263, EphA253–62, EphA263–75,
and EphA2663–678. These probes were then used to quantitate and
provide additional phenotypic characteristics of circulating CD4+
T cells in HLA-DR4+ cancer patients.
We observed that TAA-specific CD4+ T cells were readily
detectable in the peripheral blood of melanoma patients, regard-
less of whether these individuals had AD or if they were NED as
a consequence of therapeutic intervention. Notably, the frequen-
cies of TAA-specific CD4+ T cells were statistically elevated in
patients with AD, whereas NED female patients on average dis-
played approximately twofold higher levels of TAA-specific Th
cells when compared to male patients. Such tendencies were not
observed for Flu-specific CD4+ T cell populations in these same
patients. We believe that the former result may simply reflect the
continued “booster” capacity of cross-presented TAA in patients
FIGURE 3 | Frequencies of antigen-specific CD4+ T cells in the
peripheral blood of melanoma patients as a function of disease stage.
Frequencies of antigen-specific CD4+ T cells in melanoma patient PBMC
was determined using PE-labeled HLA-DR4/peptide tetramers and flow
cytometry as described in Figure 1. Patients were segregated based on
clinical disease stage, with each diamond symbol representing data from a
single patient. Heavy horizontal bars represent mean for each disease
stage, with linear-regression trend lines overlaying each graph.
with AD, which becomes limiting in patients characterized as
NED (barring the presence of occult disease in these individu-
als). It remains unclear why higher frequencies of EphA2- and
MAGE-6-specific CD4+ T cells were identified in female patients,
although it has been previously reported that female melanoma
patients have a generally better prognosis (i.e., longer survival)
when compared to their male counterparts (30). It would be
tempting to speculate that the presence of greater numbers of TAA-
specific CD4+ T cells or the reported ability of CD4+ T cells from
women vs. men to mount IFN-γ/IL-2-dominated recall responses
to (pathogenic) restimulation (31) could serve as a foundation for
understanding such clinical observations. The differential impact
of reproductive hormones (estrogen enhancing vs. testosterone
blunting) on antigen-specific T cell fate and function (32–34)
must also clearly be considered within the context of our surpris-
ing findings. Additional analyses of a larger cohort of melanoma
patients that have been immunologically interrogated in a lon-
gitudinal fashion to corroborate such a linkage would clearly be
warranted.
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FIGURE 4 | Enhanced apoptosis ofTAA (vs. FluM1)-specific CD4+ T cells
in the peripheral blood of melanoma patients. Flow cytometric analysis
of CD4+ HLA-DR4/peptide tetramer+ T cells was performed as described in
Figure 1. (A) Peripheral blood antigen-specific (tetramer+) CD4+ T cells
from patients Mel093 and Mel096 were apoptotic status based on staining
for Annexin-V and 7-AAD as monitored by multi-parameter flow cytometry
(as described in Section “Materials and Methods”). Frequencies of early
(Annexin-V+/7-AADneg) vs. total (Annexin-V+ regardless of 7-AAD status)
apoptotic events is tabulated. (B) Cumulative results for total CD4+ T cells
and antigen-specific CD4+ T cells are depicted in Box plot format, with
heavy horizontal lines representing the mean for each group, and whisker
bars representing 5th and 95th percentiles (n=13; i.e., Mel036-Mel104).
*p<0.05 vs. FluM1 (T -test).
Since patients with AD are subjected to immunologic condi-
tions of chronic antigenic stimulation, we believe it appropriate to
consider general paradigms of eroding immune function in other
clinically relevant models, such as chronic infectious diseases. In
states of chronic viral infection, diminished Type-1 immunity (35)
mediated via enhanced susceptibility of T cells to AICD (21, 28,
36) and/or the development of viral-specific Treg functional activ-
ity have been associated with the host’s inefficiency in clearing
pathogens (37–39). Based on our current phenotypic analyses,
FIGURE 5 |TAA-specific CD4+ T cells in the peripheral blood of
melanoma patients undergo enhanced rates of apoptosis (vs.
Flu-M1-specific CD4+ T cells) at all stages of disease progression.
Frequencies of total apoptotic events among total CD4+ T cells and
antigen-specific CD4+ T cells in melanoma patient PBMC (n=13) were
determined using PE-labeled HLA-DR4/peptide (pooled TAA or FluM1)
tetramers and flow cytometry as described in Figure 4. Patients were
segregated based on clinical disease stage, with each diamond symbol
representing data from a single patient. Linear-regression trend lines
overlay each graph.
we found little evidence for TAA-specific CD4+CD25hi+ T (Treg)
cells, and indeed, no elevation in the frequency of this subset of
T cells in the peripheral blood of patients vs. that reported for
normal controls, consistent with a previous report for the bulk
population of Treg (20). This leaves a likely possibility that the
enhanced sensitivity of TAA-specific CD4+ T cells (especially the
Th1-type) to AICD as a primary cause for our observation of Type-
1 deficiency in melanoma patients with AD (17, 40). Our analyses
in melanoma patients supported the elevated pro-apoptotic phe-
notype of TAA-specific (vs. FluM1-specific) CD4+ T cells based
on Annexin-V+ staining in flow cytometry assays, which was
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FIGURE 6 |TheType-1 subset ofTAA-specific CD4+ T cells is a minority
cohort that exhibits preferential sensitivity to apoptosis in the
peripheral blood of melanoma patients. Multi-parameter flow cytometry
including intracellular staining for the Type-1 transcription factor T-bet (as
described in Section “Materials and Methods”) was used to determine the
frequency of Type-1 T cells among total CD4+ T cells or antigen-specific
CD4+ T cell subsets [(A); n=4; i.e., Mel612, Mel633, Mel634, Mel635], the
frequency of apoptotic (Annexin-V+) events among Type-1 (T-bet+) vs.
non-Type-1 TAA-specific CD4+ T cells (B,C). (B) Data derived from T cells
obtained from patient Mel633.
clearly enriched within the Type-1 (T-bet+) sub-population of
TAA-tetramer+ events across all tumor-associated antigenic speci-
ficities evaluated in this study. We have also obtained preliminary
evidence for similar enrichment of Annexin-V+ events among
CD4+ T cells reactive with TAA (but not FluM1) tetramer probes
in HLA-DR4+ patients with RCC (Figure 7).
Whiteside’s group has previously reported that in patients
with head-and-neck carcinoma or melanoma that circulating bulk
FIGURE 7 |TAA-specific CD4+ T cells in the peripheral blood of RCC
patients undergo enhanced rates of apoptosis (vs. Flu-M1-specific
CD4+ T cells). In (A), frequencies of FluM1- and EphA2-specific CD4+ T
cells in the PBMC of 5 HLA-DR4+ RCC patients with AD were determined
using PE-labeled HLA-DR4/peptide tetramers and flow cytometry as
described in Figure 1. In (B), frequencies of total apoptotic events amongst
total CD4+ T cells and antigen-specific CD4+ T cells in RCC patient PBMC
(n=5) were determined using PE-labeled HLA-DR4/peptide (pooled TAA or
FluM1) tetramers and flow cytometry as described in Figure 4.
CD8+ (but not CD4+) T cells frequently exhibit an early apop-
totic phenotype (41–43), which may be related to an increased
ratio of Bax/Bcl-2 or Bax/Bcl-xL expression within CD8+ T cells
of patients (42). Our data would predict that a similar differ-
ential imbalance between pro (Bax)-/anti (Bcl-2, Bcl-xL, Mcl-1,
Xiap)-apoptotic proteins is likely to occur within the subset of
TAA-specific (but not bulk or viral-specific) CD4+ T cells in the
peripheral blood of melanoma or RCC patients with AD.
In principle, such a clinical defect can be therapeutically cor-
rected since alterations of pro- and anti-apoptotic molecules in
lymphocytes may be modulated by multiple signals, provided it
is via the cognate TCR, co-stimulatory/co-inhibitory molecules,
as well as by cytokines. In particular, while in vivo-activated
CD4+CD45RO+ T cells are susceptible to apoptosis, they can be
“rescued” by cytokines or chemokines (44), including IL-2, IL-
6, IL-7, IL-15, and CXCL12. Checkpoint inhibitors (anti-CTLA4,
anti-PD-1/anti-PD-L1, anti-LAG-3, anti-BTLA), as well as ago-
nists of CD40 or TLR, are also known to improve anti-tumor T
cell survival (45–49). In addition, since tumor-derived exosomes
serve as systemic instigators of T cell apoptosis (50), future inter-
ventional strategies may also be expected to improve the survival
of anti-TAA Th1 cells in patients with cancer.
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